Michael T. Lin, M.D.July 15, 2022

FDA 483 - Michael T. Lin, M.D. - July 15, 2022

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Record Details

An FDA inspection of Michael T. Lin, M.D., a clinical investigator in New York, NY, revealed a significant violation related to human subject protection. The firm failed to obtain informed consent from a human subject prior to administering a study drug and conducting related tests, as required by protocol and federal regulations. This indicates a serious lapse in ethical and regulatory compliance for clinical trials.

Company: Michael T. Lin, M.D.
Inspection Date: July 15, 2022
Product Type: Drugs
Office: Division of Human and Animal Food Operations - East I
Person: Omadevi Somai

Open in Dashboard

ID · cf90a592-55c4-4905-8cfb-d91d453cb135